Connect with us

Health

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia – Wiley

The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations,…

Published

on

Article feature image

Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel beta coronavirus, has led to unprecedented healthcare challenges on a global scale. Development of anti-viral immunity is key to reducing spread of infection and gaining pandemic control. Impressive collaborative efforts have led to the rapid development of multiple efficacious vaccines against SARS-CoV-2. BNT162b2 is a nucleoside-modified mRNA that encodes a full-length Spike that is stabilised in the pre-fusion…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending